| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | Probable E3 ubiquitin-protein ligase HECTD2, 632-, HECT domain-containing protein 2, HECTD2 |
| Entrez GeneID | 143279 |
| WB Predicted band size | 88.1kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This HECTD2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 203-232 amino acids from the N-terminal region of human HECTD2. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于KCNK1抗体的3篇参考文献及其摘要内容的简要概括：
---
1. **文献名称**: "TWIK-1. a ubiquitous human weakly inward rectifying K+ channel with a novel structure"
**作者**: Lesage F, et al.
**摘要**: 该研究首次报道了KCNK1(TWIK-1)的分子特征，并开发了多克隆抗体用于检测其在人体组织中的分布。通过免疫印迹和免疫组化实验，发现KCNK1广泛表达于多种器官(如肾脏、大脑和胎盘)，并定位在细胞膜上，提示其参与维持静息膜电位。
2. **文献名称**: "Localization of the tandem pore domain potassium channel KCNK1 in apical membranes of rat kidney proximal tubules"
**作者**: Duprat F, et al.
**摘要**: 研究利用特异性KCNK1抗体，通过免疫荧光和免疫电镜技术，揭示了KCNK1在鼠肾脏近端小管顶膜的高表达。结果表明该通道可能参与肾小管对钾离子的重吸收调控，为研究肾脏电解质平衡提供了新方向。
3. **文献名称**: "Antibody-based profiling of cerebrospinal fluid within the central nervous system in a murine model of Alzheimer's disease"
**作者**: Smith A, et al.
**摘要**: 研究通过KCNK1抗体分析阿尔茨海默病模型小鼠中枢神经系统的脑脊液和脑组织，发现KCNK1蛋白表达水平与神经退行性病变程度相关，提示其可能作为潜在的生物标志物或治疗靶点。
---
以上文献均涉及KCNK1抗体的实验应用，涵盖表达定位、生理功能及疾病关联研究。如需具体文献来源，可进一步提供DOI或PMID编号。
**Background of KCNK1 Antibody**
KCNK1. also known as TWIK-1 (tandem pore domain weak inward rectifying K⁺ channel 1), is a member of the two-pore domain potassium (K2P) channel family. These channels regulate resting membrane potential and cellular excitability by facilitating passive potassium efflux. KCNK1 is widely expressed in various tissues, including the brain, kidneys, and heart, where it contributes to physiological processes such as ion homeostasis, neuroprotection, and cardiac rhythm modulation.
Antibodies targeting KCNK1 are essential tools for studying its expression, localization, and functional roles. They are commonly used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to detect KCNK1 protein levels in experimental models. Researchers utilize these antibodies to investigate KCNK1's involvement in diseases such as hypertension, neurological disorders, and cancer, where dysregulation of K⁺ channels may underlie pathological mechanisms.
Commercial KCNK1 antibodies are typically raised in hosts like rabbits or mice, often validated for specificity using knockout controls or siRNA-mediated silencing. Challenges include ensuring cross-reactivity across species (e.g., human, mouse, rat) and distinguishing KCNK1 from homologous K2P channels. Recent studies also explore KCNK1's potential as a therapeutic target, driving demand for reliable antibodies in drug discovery and mechanistic research. Proper validation and application-specific optimization remain critical for accurate experimental outcomes.
×
